These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36366484)

  • 1. An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant.
    Zhang H; Hu B; Lv P; Liu Y; Guo M; Wu Z; Zhou K; Dai M; Yu X; Liu Z; Yu B; Xu L; Guo M; Cai K; Li Y
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
    Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
    J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.
    Arora P; Zhang L; Krüger N; Rocha C; Sidarovich A; Schulz S; Kempf A; Graichen L; Moldenhauer AS; Cossmann A; Dopfer-Jablonka A; Behrens GMN; Jäck HM; Pöhlmann S; Hoffmann M
    Cell Host Microbe; 2022 Aug; 30(8):1103-1111.e6. PubMed ID: 35588741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE2-Decorated Virus-Like Particles Effectively Block SARS-CoV-2 Infection.
    Bayraktar C; Kayabolen A; Odabas A; Durgun A; Kok I; Sevinc K; Supramaniam A; Idris A; Bagci-Onder T
    Int J Nanomedicine; 2024; 19():6931-6943. PubMed ID: 39005960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
    Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
    mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2.
    Zhang L; Narayanan KK; Cooper L; Chan KK; Skeeters SS; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
    EMBO Mol Med; 2022 Nov; 14(11):e16109. PubMed ID: 36094679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
    Kumar S; Patel A; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Davis-Gardner ME; Edara VV; Linderman S; Nayak K; Dixit K; Sharma P; Bajpai P; Singh V; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Mantus G; Goel PK; Rahi M; Davis CW; Wrammert J; Godbole S; Henry AR; Douek DC; Suthar MS; Ahmed R; Ortlund E; Sharma A; Murali-Krishna K; Chandele A
    Sci Adv; 2022 Oct; 8(40):eadd2032. PubMed ID: 36197988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern.
    Du W; Hurdiss DL; Drabek D; Mykytyn AZ; Kaiser FK; González-Hernández M; Muñoz-Santos D; Lamers MM; van Haperen R; Li W; Drulyte I; Wang C; Sola I; Armando F; Beythien G; Ciurkiewicz M; Baumgärtner W; Guilfoyle K; Smits T; van der Lee J; van Kuppeveld FJM; van Amerongen G; Haagmans BL; Enjuanes L; Osterhaus ADME; Grosveld F; Bosch BJ
    Sci Immunol; 2022 Jul; 7(73):eabp9312. PubMed ID: 35471062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AlphaFold2-Enabled Atomistic Modeling of Structure, Conformational Ensembles, and Binding Energetics of the SARS-CoV-2 Omicron BA.2.86 Spike Protein with ACE2 Host Receptor and Antibodies: Compensatory Functional Effects of Binding Hotspots in Modulating Mechanisms of Receptor Binding and Immune Escape.
    Raisinghani N; Alshahrani M; Gupta G; Xiao S; Tao P; Verkhivker G
    J Chem Inf Model; 2024 Mar; 64(5):1657-1681. PubMed ID: 38373700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
    Ikemura N; Taminishi S; Inaba T; Arimori T; Motooka D; Katoh K; Kirita Y; Higuchi Y; Li S; Suzuki T; Itoh Y; Ozaki Y; Nakamura S; Matoba S; Standley DM; Okamoto T; Takagi J; Hoshino A
    Sci Transl Med; 2022 Jun; 14(650):eabn7737. PubMed ID: 35471044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
    Gruell H; Vanshylla K; Korenkov M; Tober-Lau P; Zehner M; Münn F; Janicki H; Augustin M; Schommers P; Sander LE; Kurth F; Kreer C; Klein F
    Cell Host Microbe; 2022 Sep; 30(9):1231-1241.e6. PubMed ID: 35921836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
    Shah M; Woo HG
    Front Immunol; 2021; 12():830527. PubMed ID: 35140714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins.
    Xu Y; Wu C; Cao X; Gu C; Liu H; Jiang M; Wang X; Yuan Q; Wu K; Liu J; Wang D; He X; Wang X; Deng SJ; Xu HE; Yin W
    Cell Res; 2022 Jul; 32(7):609-620. PubMed ID: 35641567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2.
    Wang R; Zhang Q; Zhang R; Aw ZQ; Chen P; Wong YH; Hong J; Ju B; Shi X; Ding Q; Zhang Z; Chu JJH; Zhang L
    Front Immunol; 2022; 13():854952. PubMed ID: 35784344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors.
    Weidenbacher PA; Waltari E; de Los Rios Kobara I; Bell BN; Morris MK; Cheng YC; Hanson C; Pak JE; Kim PS
    Nat Chem Biol; 2022 Nov; 18(11):1270-1276. PubMed ID: 36076082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
    Zhu Y; Hu Y; Liu N; Chong H; He Y
    Antiviral Res; 2022 Dec; 208():105445. PubMed ID: 36265805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
    Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.